Results 61 to 70 of about 7,531 (200)

ALVAC-HIV B/C candidate HIV vaccine efficacy dependent on neutralization profile of challenge virus and adjuvant dose and type.

PLoS Pathogens, 2019
The ALVAC-HIV clade B/AE and equivalent SIV-based/gp120 + Alum vaccines successfully decreased the risk of virus acquisition in humans and macaques. Here, we tested the efficacy of HIV clade B/C ALVAC/gp120 vaccine candidates + MF59 or different doses of
Luca Schifanella, Susan W Barnett, Massimiliano Bissa, Veronica Galli, Melvin N Doster, Monica Vaccari, Georgia D Tomaras, Xiaoying Shen, Sanjay Phogat, Ranajit Pal, David C Montefiori, Celia C LaBranche, Mangala Rao, Hung V Trinh, Robyn Washington-Parks, Namal P M Liyanage, Giacomo Gorini, Dallas R Brown, Frank Liang, Karin Loré, David J Venzon, William Magnanelli, Michelle Metrinko, Josh Kramer, Matthew Breed, Galit Alter, Ruth M Ruprecht, Genoveffa Franchini   +27 more
doaj   +1 more source

Influenza Vaccination of young children or Antibody Immune Response and Protection after Inactivated Influenza Vaccine in Children – A Literature Review [PDF]

, 2020
Influenza virus infection is a major cause of morbidity and mortality in at risk populations. Children, especially under the age of two, are at an increased risk of complications associated with influenza virus infection.
wall, danielle
core   +1 more source

New cutaneous vaccine adjuvant that STINGs a little less [PDF]

, 2016
Cutaneous vaccination can be a challenge because the development of local skin inflammation is often unavoidable. Thus, it is important to identify and validate new vaccine adjuvants that enhance immunization without the burden of inflammation.
Caucheteux, Stephane, Piguet, Vincent
core   +1 more source

The issues caused by misinformation—How workers and organizations deal with it: A systematic literature review. An Annual Review of Information Science and Technology (ARIST) paper

Journal of the Association for Information Science and Technology, Volume 77, Issue 1, Page 133-162, January 2026.
Abstract In today's digital age, misinformation propagates rapidly through digital channels, blurring the lines between truth and fiction, and challenging the foundations of trust in information sources. Although affecting all spheres of life, misinformation poses a significant threat to workers highlighting a critical intersection between ...
Ashwani Malhotra, Nina Evans, Jing Gao, Jia Tina Du, Connie Zheng   +4 more
wiley   +1 more source

MF59-adjuvanted vaccines: increased immunogenicity with an optimal safety profile

Expert Review of Vaccines, 2003
The need to enhance the immunogenicity of purified subunit antigens has prompted the development of several new adjuvants. However, many of these new molecules have demonstrated a reactogenicity profile that is not suitable for their inclusion in vaccines for human use.
Audino, Podda, Giuseppe, Del Giudice
openaire   +2 more sources

Safety and immunogenicity of a subtype C ALVAC-HIV (vCP2438) vaccine prime plus bivalent subtype C gp120 vaccine boost adjuvanted with MF59 or alum in healthy adults without HIV (HVTN 107): A phase 1/2a randomized trial.

PLoS Medicine
BackgroundAdjuvants are widely used to enhance and/or direct vaccine-induced immune responses yet rarely evaluated head-to-head. Our trial directly compared immune responses elicited by MF59 versus alum adjuvants in the RV144-like HIV vaccine regimen ...
Zoe Moodie, Erica Andersen-Nissen, Nicole Grunenberg, One B Dintwe, Faatima Laher Omar, Jia J Kee, Linda-Gail Bekker, Fatima Laher, Nivashnee Naicker, Ilesh Jani, Nyaradzo M Mgodi, Portia Hunidzarira, Modulakgota Sebe, Maurine D Miner, Laura Polakowski, Shelly Ramirez, Michelle Nebergall, Simbarashe Takuva, Lerato Sikhosana, Jack Heptinstall, Kelly E Seaton, Stephen De Rosa, Carlos A Diazgranados, Marguerite Koutsoukos, Olivier Van Der Meeren, Susan W Barnett, Niranjan Kanesa-Thasan, James G Kublin, Georgia D Tomaras, M Juliana McElrath, Lawrence Corey, Kathryn Mngadi, Paul Goepfert, HVTN 107 Protocol Team   +33 more
doaj   +1 more source

Safety and immunogenicity profiles of an adjuvanted seasonal influenza vaccine in Guatemalan children

Journal of Infection in Developing Countries, 2014
Introduction: The efficacy of non-adjuvanted seasonal influenza vaccine in young children is considered to be suboptimal.  This study compared the safety and immunogenicity profiles of MF59-adjuvanted, trivalent, influenza vaccine (ATIV) and non ...
Adib Rodriguez Solares, Carlos Grazioso Aragon, Rodolfo Urruela Pivaral, David Prado-Cohrs, Victor Sales-Carmona, Michele Pellegrini, Nicola Groth   +6 more
doaj   +1 more source

Molecular Variations in Glycoprotein B of Asian Human Cytomegalovirus: Potential Impact on Virus Entry and Immune Evasion in Ocular Diseases

Journal of Medical Virology, Volume 98, Issue 1, January 2026.
ABSTRACT Human cytomegalovirus (HCMV)‐associated ocular diseases have gained increasing attention due to a recent rise in cases diagnosed in Asia. A glycoprotein encoded by the virus UL55 gene, glycoprotein B (gB), is essential for viral entry and a primary target for naturally‐produced antibodies and vaccine development.
Tantri Lestari, Nobuyo Yawata, Gabriel Gonzalez, Hiroko Miyadera, Daisuke Motooka, Yuko Imamura, Hiroya Oki, Yasuo Mori, Mariko Shirane, Seik‐Soon Khor, Yosuke Omae, Mihoko Shimada, Dyah Ayu Windy, Satoko Nakano, Hiroki Tsutsui, Shiori Kuramoto, Chihiro Fukui, Riku Nakamura, Satoshi Yamana, Toshikatsu Kaburaki, Hisashi Mashimo, Hiroshi Takase, Ryoji Yanai, Eiichi Hasegawa, Kensuke Shibata, Makoto Yawata, Katsushi Tokunaga, Nobuyuki Ohguro, Koh‐Hei Sonoda   +28 more
wiley   +1 more source

The Protective Effects of the A/ZJU01/ PR8/2013 Split H7N9 Avian Influenza Vaccine Against Highly Pathogenic H7N9 in BALB/c Mice

Cellular Physiology and Biochemistry, 2018
Background/Aims: Since the first case of novel H7N9 infection was reported, China has experienced five epidemics of H7N9. During the fifth wave, a highly pathogenic H7N9 strain emerged. In order to assess whether the H7N9 vaccine based on A/Zhejiang/DTID-
Xiao-Xin Wu, Xi-Long Deng, Dong-Shan Yu, Wei Yao, Hui-Lin Ou, Tian-Hao Weng, Chen-Yu Hu, Feng-Yu Hu, Nan-Ping Wu, Hangping Yao, Fu-Chun Zhang, Lan-Juan Li   +11 more
doaj   +1 more source

The cytomegalovirus gB/MF59 vaccine candidate induces antibodies against an antigenic domain controlling cell-to-cell spread

Nature Communications, 2023
A gB/MF59 vaccine candidate for human cytomegalovirus (HCMV) provided partial protection in organ transplant patients. Here, the authors identify antibody responses in trial participants that target virally infected cells to control cell-to-cell spread ...
A. C. Gomes, I. A. Baraniak, A. Lankina, Z. Moulder, P. Holenya, C. Atkinson, G. Tang, T. Mahungu, F. Kern, P. D. Griffiths, M. B. Reeves   +10 more
doaj   +1 more source